Feature | September 13, 2013| Patrick Antoun, M.D., and Jeffrey A. Breall, M.D., Ph.D.

Justifying the Use of Vascular Closure Devices

Some centers use closure devices to speed ambulation, cut nursing time

Vascular closure devices (VCD) were first introduced in the early 1990s with a goal to achieve quick hemostasis, thus reducing patients’ stay in the hospital (shorter time to ambulation) as well as faster turnover times for cardiac catheterization laboratories. 

All closure devices have a known cost, as well as a finite failure and complication rate. Perhaps this is why VCDs still face resistance in many institutions. Although percutaneous coronary intervention (PCI) using coronary stents is now standard of care, many new devices and/or treatment of bifurcation lesions require larger sheath and guidecatheter sizes. It thus seems intuitive to move away from bulky uncomfortable sand bags and long hours of bed rest when trying to achieve post-procedural hemostasis. However, VCDs are still not widely used and this is driven, in part, by the lack of reimbursement of such devices to this date. The Centers for Medicare and Medicaid Services (CMS), for example, does not reimburse for any of these items specifically, and the commercial indemnity carriers are mixed, but tend to follow the CMS practice.

Types of Devices and Usage

VCDs exist in a variety of models. These include plug, patch, suture and staple models. Many companies have improved on their basic designs in an effort to decrease complication rates while keeping these devices fast and easy to deploy. Several studies followed by meta-analyses were published to date demonstrating non-inferiority to manual compression in terms of their complication rates and patient comfort. 

However, what VCDs offer that manual compression does not, is essentially better cath lab efficiency — probably faster patient ambulation times and subsequent discharge. In fact, these devices have proven to be very convenient following PCI where the patient can be discharged the same day, even if their procedures were performed late on their appointment day. Although the latter observation was never backed by a solid randomized control trial, it is our personal approach to discharge all uncomplicated elective PCIs on the same day. Some authors suggested a cost benefit with the routine use of VCDs with PCI. However, VCDs may make less sense, in an era of increasing radial access use. Certainly the VCD may be replaced by a radial wristband compression device, but a simple gauze and tape may accomplish the same thing at a lower cost during radial interventions. What about routine diagnostic angiography? There is no definite answer. With the use of smaller catheters during routine diagnostic studies, there really is no need for the use of VCDs. Hemostasis is usually quickly achieved with minimal patient discomfort, even with same day discharge. 

Anticoagulation and Operator Skill

Increasing use of bivalirudin in many labs with less intense anticoagulation during PCI has accomplished two things — less access site bleeding and the appearance of more effective VCDs. How much VCD efficacy over the past 10 years is a result of VCD advances versus changes in anticoagulation strategy is only speculative.

Operator skill also plays a large role with these devices. Most manufacturers (as well as the FDA) require that the first handful of cases be proctored by a sales representative or clinical specialist. Vendors often blame adverse outcomes on inexperienced operators rather than the device itself. Certainly there is no device that is “fool-proof” (although device reps may try to make you believe otherwise). Some require several steps in a specific sequence to use the device properly. Our experience would suggest the more frequently a device is used, the greater its success rate.

Appropriate Use 

VCDs can be very useful when used appropriately in select patients. There are no guidelines to date that dictate their optimal use. Well-designed randomized trials are perhaps needed to answer once and for all the concerns raised by published meta-analyses thus far (although this is unlikely to occur). This could be followed by developing appropriate use criteria for VCDs that would in turn facilitate renegotiation of their reimbursement. As in many other interventional cardiology arenas, the landscape, technologies and practice patterns are rapidly changing, making hard and fast recommendations somewhat difficult.   

Comparison Chart

This article served as an introduction to 3 comparison charts covering hemostasis management devices. Links to the charts for "Hemostasis Management Compression Devices," "Hemostasis Management Hemostatic Pads," and "Vascular Closure Devices" can be found by clicking on the "comparison charts" tab at the top of the page.  Participants on the charts include:

AccessClosure Inc. — www.accessclosure.com

Advanced Vascular Dynamics — www.compressar.com

Arstasis — www.arstasis.com

Biolife LLC — www.statseal.com

Maquet — ca.maquet.com

Marine Polymer Technologies — www.syvek.com

St. Jude Medical — www.sjm.com

Terumo Medical — www.terumois.com

TZ Medical Inc. — www.tzmedical.com

Vascular Solutions — www.vasc.com

Z-Medica LLC — www.z-medica.com

Scranton Gillette Communications obtained the model specifications
from the manufacturers.



Related Content

Shimadzu, MIX package, Trinias Cardiovascular suites, U.S. availability

Image courtesy of Shimadzu Medical Systems

Technology | Cath Lab| October 08, 2015
Shimadzu Medical Systems USA announced the availability of the MIX package for the Trinias Cardiovascular suites. Based...
ORSIF, radiation exposure for interventionalists, greater on left side of head, Ehtisham Mahmud
Feature | Radiation Dose Management| October 06, 2015
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Overlay Init